Innovation in Injectables: Join Us for the 21st PDA Universe of Pre-Filled Syringes and Injection Devices Conference

The demand for prefilled syringes is growing exponentially around the world. Recent data values the injectable drug delivery market at $124.69 billion USD in 2024 with anticipated growth to $229.21 billion USD by 2032. This aligns with a compound annual growth rate (CAGR) of 7.21% in the next eight years, and the growth will not stop there. In response to this dramatic rise in demand, pharmaceutical and biotech leaders must stay ahead of the curve, innovate proactively, and understand the evolving technologies, trends and new challenges driving the industry toward its future. 

 Information, Insights and Connection 

 How do you ensure you’re ahead of the curve with cutting-edge industry knowledge? There is no better opportunity to learn first-hand from the injectable industry’s top experts than the PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024. 

 As the leading event for professionals in injectable manufacturing, the conference will provide expertise and insights about the latest innovations and trends in device technology, regulatory, manufacturing and quality control facing new challenges like sustainability. Celebrating its 21st year, key players will flock to Phoenix, Arizona, U.S., on 22-23 October for two days of shared knowledge and learning. The event is designed to spark connections leading to collaborative relationships and long-term partnerships. Plus, to celebrate the importance and influence of the market, top innovators will be awarded the Drug Delivery Innovation Award including Best Partnership. 

 Industry Challenges 

 With the rise in chronic diseases, the injectable sector faces growing challenges in the form of additional approval obstacles and a higher demand for blockbuster products and small-batch drugs. Navigating the complex and evolving requirements for combination products is a test and critical undertaking for many injectable drug products. 

 The shift from intravenous (IV) to subcutaneous (SC) is ushering in an emerging field of devices that exceed 2ml to support patient self-administration. In response, the industry needs to adjust the drug development process with new, larger devices that address unique requirements. 

 The conference will also address sustainability, which is also a key challenge. As a high-consumption industry with heavy plastic production, we need to focus on making smart, environmentally conscious decisions as a responsible member of the value chain notably considering carbon emission reduction and device recycling. 

 Throughout the conference, experts will explore emerging trends in the injectable delivery sector, including the growing demand for innovative home care solutions that allow for self-administration. Based on increasing popularity among patients, the development of digital systems that add connectivity to drug delivery devices such as autoinjectors is critical. 

 Experiential Agenda 

 This two-day event begins with a plenary session, setting the stage with a session focused on the latest regulatory developments and guidance for combination products, common pitfalls in their development and approval, as well as lessons learned, best practices, and helpful strategies. A second panel will address the marketplace and what its growth means for delivery options including a look at current challenges and untapped opportunities.  

 Attendees will then progress to a series of concurrent sessions focused on critical industry and patient topics such as holistic design approaches for combination products; the nuances of autoinjectors and their role in high-dose delivery; quality control innovations; the rise of AI in visual inspections; the human side of product development; and many more. The opening-day evening will conclude with a lively reception replacing the day’s work with relaxation and a chance to socialize with peers and colleagues.  

 Day two will feature lightning presentations—six-minute presentations offering impactful insights into emerging research and innovations. Then, a panel on drug delivery platforms and the unique perspectives that define the market will spark a dynamic discussion. Both device manufacturers and pharmaceutical industry experts will share their viewpoints and experiences as they discuss strategies, benefits, and challenges in deploying standardized delivery device platforms across multiple drug products. Throughout the day, concurrent sessions will highlight topics including drug-device combination products, large-volume drug delivery, and sustainability.  

 Of course, no conference would be complete without addressing the trending obesity drug landscape and the transformation of drug delivery as it relates to GLP-1 and insulin. The day concludes with a final panel on cross-industry collaboration to boost sustainability. l 

 Added Value 

 Throughout the conference, the exhibition hall will feature over 120 vendors showcasing top-of-the-line equipment and innovative solutions. Attendees can engage with leading service providers and explore new partnership opportunities and unparalleled technologies. Guided poster tours will also provide detailed explanations of groundbreaking projects from some of the industry’s leading minds.  

 Networking opportunities are planned throughout the entire conference to connect with peers, exchange ideas and experience as well as build valuable relationships with the major players driving the industry’s rapid evolution and improvements in patient life. The main conference will also be complemented with specialized training and the Combination Products Workshop to bridge theory to practice. 

 Don't miss this opportunity to stay ahead of industry trends and enhance your knowledge in injectable manufacturing alongside the world’s most innovative industry leaders. Register today to secure your spot at the PDA Universe of Pre-Filled Syringes and Injection Devices Conference and be part of the future of injection device innovation. 

We hope to see you there!